Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

NCT06383819 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Post-Acute COVID-19 Syndrome
Lung Disease With Polymyositis
Fibrosis
Lung Diseases, Interstitial
Lung; Disease, Interstitial, With Fibrosis

Interventions

DRUG: Longidaza®
DRUG: Placebo

Sponsor

NPO Petrovax